Le Lézard

Encoded Therapeutics Presents Positive Interim Efficacy Data from Initial Dose Levels of Phase 1/2 Trials Evaluating ETX101 Gene Therapy in Dravet Syndrome

Encoded Therapeutics Inc., a clinical-stage biotechnology company developing genetic medicines for severe neurological disorders, today announced positive interim results from its ongoing POLARIS ...

Do I have Christmas tree syndrome and how can I stop symptoms?

Every Christmas, it’s the same story for some households. The tree goes up, and within a day or two, you’re sneezing, congested, itchy-eyed and wondering why you suddenly feel awful. If that sounds ...

Northeast Louisiana toddler battles rare genetic condition that may be one-of-a-kind worldwide

In Addy’s case, her parents say they often had to educate her medical teams on what the syndrome meant and why they were so ...

Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has granted ...
Le Lézard

Encoded Therapeutics to Present Interim Phase 1/2 Clinical Data on ETX101, the First One-time Gene Therapy in Development for Dravet Syndrome, at the 2025 American Epilepsy ...

Encoded Therapeutics Inc., a clinical-stage genetic medicines company, today announced upcoming presentations of interim clinical data from its ongoing POLARIS Phase 1/2 open-label trials evaluating ...